Related Experiment Video
Updated: Jun 29, 2026
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective
Véronique Hofman1, Guylène Rignol1, Baharia Mograbi1
1IHU RespirERA, FHU OncoAge, Côte d'Azur University, Laboratory of Clinical and Experimental Pathology, Biobank BB-0033-00025, Pasteur Hospital, Nice, France; IRCAN, Inserm U1081, Faculty of Medicine, Nice, France.
Abstract:
Antibody-drug conjugates (ADC) as a new treatment modality have enabled novel, promising treatment options in lung cancer. However, biomarkers for the selection of appropriate treatments are still under development, posing novel challenges for tissue selection and development of companion diagnostics (CDx). In this review, we address the challenges and discuss best practice for fast, reliable and robust implementation of novel biomarkers in treatment selection of ADCs in lung cancer.
Insights
Antibody-drug conjugates offer new lung cancer treatments. Developing biomarkers for selecting patients and companion diagnostics (CDx) presents challenges, requiring robust implementation strategies for effective targeted therapy.
Area of Science:
- Oncology
- Pharmacology
- Biomarker Discovery
Background:
- Antibody-drug conjugates (ADCs) represent a promising therapeutic advancement in lung cancer treatment.
- The efficacy of ADCs is highly dependent on patient selection, necessitating reliable biomarkers.
- Current challenges include the underdevelopment of biomarkers and companion diagnostics (CDx) for ADC therapy.
Purpose of the Study:
- To review the challenges associated with biomarker development for ADCs in lung cancer.
- To discuss best practices for implementing novel biomarkers in ADC treatment selection.
- To address the need for robust companion diagnostics (CDx) in this field.
Main Methods:
- Literature review of current ADC therapies in lung cancer.
- Analysis of challenges in biomarker identification and validation.
- Discussion of strategies for companion diagnostic (CDx) development and implementation.
Main Results:
- Biomarker development for ADCs in lung cancer is critical but faces significant hurdles.
- Standardized and validated biomarkers are essential for effective patient stratification.
- Rapid and reliable implementation of biomarkers is key to realizing ADC potential.
Conclusions:
- Addressing biomarker and CDx challenges is crucial for advancing ADC therapy in lung cancer.
- Best practices for biomarker implementation will enhance treatment selection and patient outcomes.
- Further research and collaboration are needed to optimize ADC treatment strategies.
